Last reviewed · How we verify

tetracaine HCl and oxymetazoline HCL

Louisiana State University Health Sciences Center in New Orleans · FDA-approved active Small molecule

tetracaine HCl and oxymetazoline HCL is a Local anesthetic with vasoconstrictor combination Small molecule drug developed by Louisiana State University Health Sciences Center in New Orleans. It is currently FDA-approved for Topical anesthesia and hemostasis for nasal surgery and procedures.

This combination drug provides local anesthesia via tetracaine and nasal vasoconstriction via oxymetazoline to reduce bleeding and improve surgical visibility in nasal procedures.

This combination drug provides local anesthesia via tetracaine and nasal vasoconstriction via oxymetazoline to reduce bleeding and improve surgical visibility in nasal procedures. Used for Topical anesthesia and hemostasis for nasal surgery and procedures.

At a glance

Generic nametetracaine HCl and oxymetazoline HCL
SponsorLouisiana State University Health Sciences Center in New Orleans
Drug classLocal anesthetic with vasoconstrictor combination
TargetVoltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline)
ModalitySmall molecule
Therapeutic areaOtolaryngology / Surgery
PhaseFDA-approved

Mechanism of action

Tetracaine is a local anesthetic that blocks sodium channels in nerve membranes, preventing pain signal transmission in nasal tissues. Oxymetazoline is an alpha-2 adrenergic agonist that causes vasoconstriction of blood vessels in the nasal mucosa, reducing bleeding and edema during surgical procedures. Together, they provide both anesthesia and hemostasis for nasal surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about tetracaine HCl and oxymetazoline HCL

What is tetracaine HCl and oxymetazoline HCL?

tetracaine HCl and oxymetazoline HCL is a Local anesthetic with vasoconstrictor combination drug developed by Louisiana State University Health Sciences Center in New Orleans, indicated for Topical anesthesia and hemostasis for nasal surgery and procedures.

How does tetracaine HCl and oxymetazoline HCL work?

This combination drug provides local anesthesia via tetracaine and nasal vasoconstriction via oxymetazoline to reduce bleeding and improve surgical visibility in nasal procedures.

What is tetracaine HCl and oxymetazoline HCL used for?

tetracaine HCl and oxymetazoline HCL is indicated for Topical anesthesia and hemostasis for nasal surgery and procedures.

Who makes tetracaine HCl and oxymetazoline HCL?

tetracaine HCl and oxymetazoline HCL is developed and marketed by Louisiana State University Health Sciences Center in New Orleans (see full Louisiana State University Health Sciences Center in New Orleans pipeline at /company/louisiana-state-university-health-sciences-center-in-new-orleans).

What drug class is tetracaine HCl and oxymetazoline HCL in?

tetracaine HCl and oxymetazoline HCL belongs to the Local anesthetic with vasoconstrictor combination class. See all Local anesthetic with vasoconstrictor combination drugs at /class/local-anesthetic-with-vasoconstrictor-combination.

What development phase is tetracaine HCl and oxymetazoline HCL in?

tetracaine HCl and oxymetazoline HCL is FDA-approved (marketed).

What are the side effects of tetracaine HCl and oxymetazoline HCL?

Common side effects of tetracaine HCl and oxymetazoline HCL include Local irritation or burning, Transient nasal congestion rebound, Headache, Systemic sympathomimetic effects (with excessive absorption).

What does tetracaine HCl and oxymetazoline HCL target?

tetracaine HCl and oxymetazoline HCL targets Voltage-gated sodium channels (tetracaine); alpha-2 adrenergic receptors (oxymetazoline) and is a Local anesthetic with vasoconstrictor combination.

Related